文献速递骨质疏松与代谢性骨病创伤骨科

临床骨折后使用双膦酸盐与新发骨折风险

Bisphosphonate use after clinical fracture and risk of new fracture.
PubMed 文献 · Osteoporos Int · 2018-02-03

在瑞典2006至2011年≥50岁人群中,260353例临床骨折且未用过双膦酸盐者中,后续使用双膦酸盐者与未使用者匹配比较。治疗前及治疗最初6个月,使用者新发临床骨折发生率更高,但相对风险随时间下降,至12至18个月时两组发生率相近。

要点

  • 临床骨折后启动双膦酸盐前,后续使用者新发骨折发生率高于持续未使用者。
  • 治疗最初6个月,双膦酸盐使用者新发骨折发生率仍高于未使用者。
  • 至治疗12至18个月,两组新发骨折发生率相近,相对风险随时间下降。

核心结论

  • 双膦酸盐治疗期间新发骨折的相对风险下降,该趋势与有益治疗效果一致,因双膦酸盐用于降低高骨折风险。

研究设计与样本

  • 基于瑞典2006至2011年≥50岁人群的数据,共3329400人。
  • 其中260353例发生临床骨折且当时未用过双膦酸盐。
  • 后续接受双膦酸盐者按性别、出生年份及初始骨折类型和年份与最多3名未使用者匹配。
  • 最终队列83104人,其中双膦酸盐使用者占26.3%。

主要发现

  • 从初始骨折到启动双膦酸盐期间,后续使用者任何新发临床骨折发生率为175.1/1000人年,持续未使用者为75.9/1000人年(HR 2.30,95%CI 2.19至2.41)。
  • 治疗最初6个月,使用者新发骨折发生率为128.8/1000人年,未使用者为90.2/1000人年(HR 1.41,95%CI 1.32至1.51)。
  • 治疗12至18个月,使用者新发骨折发生率为59.3/1000人年,未使用者为55.3/1000人年(HR 1.03,95%CI 0.91至1.16)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Among older adults with a previous fracture, treatment for osteoporosis was initially associated with a higher risk of new fracture. However, the relative risk of new fracture decreased over time, a trend that is consistent with a beneficial effect, as treatment for osteoporosis is prescribed to reduce high fracture risks. INTRODUCTION: The purpose of this study was to examine whether bisphosphonate use is associated with a lower risk of new fracture after a clinical fracture in older adults. METHODS: Data were available for 3,329,400 adults in Sweden who were aged ≥ 50 years between 2006 and 2011. During this period, 260,353 sustained a clinical fracture and were naïve to bisphosphonates at the time. Those who subsequently received a bisphosphonate were matched to up to three others on sex, year of birth, and type and year of initial fracture. The final cohort comprised 83,104 adults (26.3% bisphosphonate users). RESULTS: During the period from initial fracture to initiation of bisphosphonate treatment, the incidence rate of any new clinical fracture was higher in those who later became bisphosphonate users than in those who remained nonusers (175.1 vs. 75.9 per 1000 person-years; hazard ratio 2.30, 95% confidence interval 2.19 to 2.41). Similarly, during the first 6 months of treatment, the incidence rate was higher in bisphosphonate users than in nonusers (128.8 vs. 90.2 per 1000 person-years; hazard ratio 1.41, 95% confidence interval 1.32 to 1.51). However, this difference decreased over time: by months 12 to 18, the incidence rate was similar in users and nonusers (59.3 vs. 55.3 per 1000 person-years; hazard ratio 1.03, 95% confidence interval 0.91 to 1.16). CONCLUSIONS: There was a decrease in the relative risk of new fracture during bisphosphonate treatment, a trend that is consistent with a beneficial treatment effect, as bisphosphonates are prescribed to reduce high fracture risks.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Bergman J, Nordström A, Nordström P, et al. Bisphosphonate use after clinical fracture and risk of new fracture. Osteoporos Int. 2018. PMID: 29397408. doi:10.1007/s00198-017-4367-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。